Creating new small-molecule treatments for triple-negative breast cancer
Development of Heterobivalent Small-Molecule Therapeutics for the Treatment of Triple-Negative Breast Cancer
This study is working on new medicines to help fight triple-negative breast cancer, which is a tough type of breast cancer that doesn't respond well to standard treatments, and aims to improve survival and quality of life for patients.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Weatherwax Biotechnologies Corporation NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11031993 on NIH RePORTER |
What this research studies
This research focuses on developing innovative small-molecule therapeutics specifically designed to target triple-negative breast cancer (TNBC), a particularly aggressive form of breast cancer that lacks effective hormone and antibody therapies. The approach aims to restore the tumor suppressor functions of mutated p53 proteins, which are prevalent in TNBC cases, thereby improving treatment outcomes. By utilizing advanced drug design techniques, the researchers hope to create compounds that can effectively combat this challenging cancer type. Patients may benefit from new treatment options that could significantly improve survival rates and quality of life.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer, particularly those with advanced stages of the disease.
Not a fit: Patients with non-triple-negative breast cancer or those whose cancer has not progressed to an advanced stage may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for triple-negative breast cancer, potentially improving survival rates and quality of life for patients.
How similar studies have performed: While the approach of targeting p53 mutations in cancer therapy is promising, it is still considered a novel and untested strategy in the context of triple-negative breast cancer.
Where this research is happening
San Francisco, United States
- Weatherwax Biotechnologies Corporation — San Francisco, United States (Active)
Researchers
- Principal investigator: Cognetta, Armand — Weatherwax Biotechnologies Corporation
- Study coordinator: Cognetta, Armand
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.